Interprofessional Perspectives on Safety Management With Targeted Therapy for B-cell Malignancies

1.00 hr(s) | ABIM , CME , MOC , NCPD

Specialty: B-cell Malignancies

Therapeutic Area(s): Hematology, Malignant , Oncology

Release Date: October 4, 2021

Expiration Date: October 3, 2022

Location: Internet Activity Enduring

In this activity, a hematologist-oncologist, cardiologist, oncology nurse, and pharmacist team up to discuss targeted agents (including BTK and BCL-2 inhibitors) in B-cell malignancies and how the team works closely together to manage toxicity and safety concerns associated with targeted therapies. Case scenarios are presented to illustrate how a collaborative approach is not only necessary for managing patients with B-cell cancers, such as CLL and MCL, but can also improve patient outcomes through monitoring and managing adverse events.

Access this activity